Royal Philips' CEO Roy Jakobs reported an improved operational performance for the healthtech and personal health company in the second quarter of 2023 − the third in a row – with comparable sales growth of 9%. The improvement was generated across all divisions and regions, he said.
The buoyancy was tempered, as has been the case for two years, by the Respironics recall and Philips’ remediation action....






